This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Weiterführende Literatur
Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 324: 71–86
Béguin S, Welzel D, Al Dieri R et al (1999) Conjectures and refutations on the mode of action of heparins. Haemostasis 29:170–178
Coller BS, Anderson K, Weisman HF (1995) New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb. Haemost. 74:302–308
Collignon F, Frydman A, Caplain H et al. (1995) Comparison of the pharmacokinetic profiles of three low molecular mass heparins — dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thrombembolism). Thromb. Haemost. 73:630–640
Colman RW, Hirsh J, Marder VJ, Salzman EW (1994) Hemostasis and Thrombosis. JB Lippincott, Philadelphia
Fareed J, Jeske W, Hoppenstaedt D et al. (1998) Low-molecular-weight heparins: Pharmacologic profile and product differentiation. Am. J. Cardiol. 82:3L–10L
Gent M et al. (1996) A randomised, blind trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339
Goldhabert SZ, Kessler GM, Heit JA et al. (1992) Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: A randomized controlled multicenter trial. J. Am. Coll. Cardiol. 20:24–30
Haas S, Haas P (1996) Niedermolekulare Heparine — Die Anwendung in Klinik und Praxis. ZETT-Verlag, Steinen
Harenberg J, Huhle G, Piazolo L, Giese C, Heene DL (1997) Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular weight heparin. Semin. Thromb. Hemost. 23:167–172
Hirsh J, Levine, MN (1992) Low molecular weight heparin. Blood 79:1–17
Kaiser B, Fareed J, Walenga JM et al (1991) In vitro studies on thrombin generation in citrated, r-hirudinized and heparinized whole blood. Thromb. Res. 64:589–596
Schrör K (1995) Antiplatelet drugs, a comparative review. Drugs 50:7–28
Schrör K (2000) Ticlopidine and clopidogrel. In: Fergusson III JJ, Chronos NAF, Harrington RA (eds.) Antiplatelet Therapy in Clinical Practice. Martin Dunitz, London, p. 93–111
Schrör K (1997) Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin. Thromb. Hemost. 23:349–356
Schrör K, Weber A-A (2003) Comparative pharmacology of GPIIb/IIIa antagonists. J. Thromb. Thrombol. 15:71–80
Thiagarajan P, Wu KK (1999) Mechanisms of antithrombotic drugs. Adv. Pharmacol. 46:297–324
Topol EJ, Byzova TV, Plow, EF (1999) Platelet GPIIb-IIIa blockers. Lancet 353:227–231
Uprichard ACG, Gallagher KP (1999) Antithrombotics. Springer Verlag, Heidelberg, New York
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Heidelberg
About this chapter
Cite this chapter
Schrör, K., Darius, H. (2004). Therapie mit Antikoagulanzien, Plättchenfunktionshemmern und Thrombolytika. In: Pharmakotherapie. Springer-Lehrbuch. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-35149-3_8
Download citation
DOI: https://doi.org/10.1007/3-540-35149-3_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-20414-5
Online ISBN: 978-3-540-35149-8
eBook Packages: Springer Book Archive